A novel ciprofloxacin-resistant subclade of h58. Salmonella typhi is associated with fluoroquinolone treatment failure

eLife

Volumn 5, Issue MARCH2016, 2016, Pages

  Thanh, Duy Pham ^a   Karkey, Abhilasha ^a   Dongol, Sabina ^a   Thi, Nhan Ho ^a   Thompson, Corinne N ^a,b,c   Rabaa, Maia A ^a,b   Arjyal, Amit ^a   Holt, Kathryn E ^d   Wong, Vanessa ^e   Thieu, Nga Tran Vu ^a   Vinh, Phat Voong ^a   Thanh, Tuyen Ha ^a   Pradhan, Ashish ^f   Shrestha, Saroj Kumar ^f   Gajurel, Damoder ^f   Pickard, Derek ^e   Parry, Christopher M ^c,g   Dougan, Gordon ^e   Wolbers, Marcel ^a,b   Dolecek, Christiane ^a,b,h   Thwaites, Guy E ^a,b   Basnyat, Buddha ^a   Baker, Stephen ^a,b,c   more..

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f CIVIL SERVICE HOSPITAL   (Nepal)

^g NAGASAKI UNIVERSITY   (Japan)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; GATIFLOXACIN; GENOMIC DNA; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM SULFATE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BLOOD ANALYSIS; BODY TEMPERATURE; DISEASE CLEARANCE; DNA EXTRACTION; DRUG TREATMENT FAILURE; EPSILOMETER TEST; GENE SEQUENCE; HUMAN; NONHUMAN; PHYLOGENY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALMONELLA ENTERICA SEROVAR TYPHI; SINGLE NUCLEOTIDE POLYMORPHISM; TYPHOID FEVER; BACTERIUM IDENTIFICATION; CLASSIFICATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECTS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEPAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CEFTRIAXONE; CIPROFLOXACIN; FLUOROQUINOLONES; GENOTYPE; HUMANS; NEPAL; SALMONELLA TYPHI; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; TYPHOID FEVER;

EID: 84962311428     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.14003     Document Type: Article

References (30)

1. Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C. 2011. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. The Lancet Infectious Diseases 11:445–454. doi: 10.1016/S1473-3099(11)70089-5.
2. Arjyal A, Basnyat B, Nhan HT, Koirala S, Giri A, Joshi N, Shakya M, Pathak KR, Mahat SP, Prajapati SP, Adhikari N, Thapa R, Merson L, Gajurel D, Lamsal K, Lamsal D, Yadav BK, Shah G, Shrestha P, Dongol S, Karkey A, Thompson CN, Thieu NTV, Thanh DP, Baker S, Thwaites GE, Wolbers M, Dolecek C. 2016. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in nepal: an open-label, two-centre, randomised controlled trial. The Lancet Infectious Diseases. doi: 10.1016/S1473-3099(15)00530-7.
3. Baker S, Duy PT, Nga TVT, Dung TTN, Phat VV, Chau TT, Turner AK, Farrar J, Boni MF. 2013. Fitness benefits in fluoroquinolone-resistant salmonella typhi in the absence of antimicrobial pressure. eLife 2:e01229–e01229. doi: 10.7554/eLife.01229.
4. CLSI. 2012. Clinical and laboratory standards institute: performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement:M100–S22.
5. Crump JA, Mintz ED. 2010. Global trends in typhoid and paratyphoid fever. Clinical Infectious Diseases 50:241–246. doi: 10.1086/649541.
6. Emary K, Moore CE, Chanpheaktra N, An KP, Chheng K, Sona S, Duy PT, Nga TVT, Wuthiekanun V, Amornchai P, Kumar V, Wijedoru L, Stoesser NE, Carter MJ, Baker S, Day NPJ, Parry CM. 2012. Enteric fever in cambodian children is dominated by multidrug-resistant H58 salmonella enterica serovar typhi with intermediate susceptibility to ciprofloxacin. Transactions of the Royal Society of Tropical Medicine and Hygiene 106:718–724. doi: 10.1016/j.trstmh.2012.08.007.
7. Firth D. 1993. Bias reduction of maximum likelihood estimates. Biometrika 80:27–38.Available: http://biomet.oxfordjournals.org/content/80/1/27.abstract. Accessed 24.June 2015. doi: 10.1093/biomet/80.1.27.
8. García-Fernández A, Gallina S, Owczarek S, Dionisi AM, Benedetti I, Decastelli L, Luzzi I. 2015. Emergence of ciprofloxacin-resistant salmonella enterica serovar typhi in italy. PLOS ONE 10:e0132065. doi: 10.1371/journal.pone.0132065.
9. Hendriksen RS, Leekitcharoenphon P, Mikoleit M, Jensen JD, Kaas RS, Roer L, Joshi HB, Pornruangmong S, Pulsrikarn C, Gonzalez-Aviles GD, Reuland EA, Al Naiemi N, Wester AL, Aarestrup FM, Hasman H. 2015. Genomic dissection of travel-associated extended-spectrum-beta-lactamase-producing salmonella enterica serovar typhi isolates originating from the philippines: a one-off occurrence or a threat to effective treatment of typhoid fever? Journal of Clinical Microbiology 53:677–680. doi: 10.1128/JCM.03104-14.
10. Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill F-X, Goodhead I, Rance R, Baker S, Maskell DJ, Wain J, Dolecek C, Achtman M, Dougan G. 2008. High-throughput sequencing provides insights into genome variation and evolution in salmonella typhi. Nature Genetics 40:987–993. doi: 10.1038/ng.195.
11. Kalbfleisch JD, Prentice RL. 2002. The Statistical Analysis of Failure Time Data John Wiley & Sons. 2nd ed Hoboken, NJ, USA: John Wiley & Sons, Inc. doi: 10.1002/9781118032985.
12. Kariuki S, Gordon MA, Feasey N, Parry CM. 2015. Antimicrobial resistance and management of invasive salmonella disease. Vaccine 33:C21–C29. doi: 10.1016/j.vaccine.2015.03.102.
13. Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J, Munyalo A, Teo YY, Holt KE, Kingsley RA, Dougan G. 2010. Typhoid in kenya is associated with a dominant multidrug-resistant salmonella enterica serovar typhi haplotype that is also widespread in southeast asia. Journal of Clinical Microbiology 48:2171–2176. doi: 10.1128/JCM.01983-09.
14. Karkey A, Thompson CN, Tran Vu Thieu N, Dongol S, Le Thi Phuong T, Voong Vinh P, Arjyal A, Martin LB, Rondini S, Farrar JJ, Dolecek C, Basnyat B, Baker S. 2013. Differential epidemiology of salmonella typhi and paratyphi a in kathmandu, nepal: a matched case control investigation in a highly endemic enteric fever setting. PLoS Neglected Tropical Diseases 7:e2391. doi: 10.1371/journal.pntd.0002391.
15. Koirala KD, Thanh DP, Thapa SD, Arjyal A, Karkey A, Dongol S, Shrestha UM, Farrar JJ, Basnyat B, Baker S. 2012. Highly resistant salmonella enterica serovar typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. Antimicrobial Agents and Chemotherapy 56:2761–2762. doi: 10.1128/AAC.06414-11.
16. Koirala S, Basnyat B, Arjyal A, Shilpakar O, Shrestha K, Shrestha R, Shrestha UM, Agrawal K, Koirala KD, Thapa SD, Karkey A, Dongol S, Giri A, Shakya M, Pathak KR, Campbell J, Baker S, Farrar J, Wolbers M, Dolecek C. 2013. Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in nepal: an open-label, randomized, controlled trial. PLoS Neglected Tropical Diseases 7:e2523. doi: 10.1371/journal.pntd.0002523.
17. Lee C-J, Su L-H, Huang Y-C, Chiu C-H. 2013. First isolation of ciprofloxacin-resistant salmonella enterica serovar typhi in taiwan. Journal of Microbiology, Immunology and Infection 46:469–473. doi: 10.1016/j.jmii.2013.01.002.
18. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R.1000. Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079. doi: 10.1093/bioinformatics/btp352.
19. Lu T, Zhao X, Drlica K. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrobial Agents and Chemotherapy 43:2969–2974.
20. Olarte J, Galindo E. 1973. Salmonella typhi resistant to chloramphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in mexico. Antimicrobial Agents and Chemotherapy 4:597–601. doi: 10.1128/AAC.4.6.597.
21. Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, Yadav B, Stepniewska K, Campbell JI, Dolecek C, Farrar JJ, Basnyat B. 2007. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS ONE 2:e542. doi: 10.1371/journal.pone.0000542.
22. Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MTG, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connerton P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O´ ’Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG. 2001. Complete genome sequence of a multiple drug resistant salmonella enterica serovar typhi CT18. Nature 413:848–852. doi: 10.1038/35101607.
23. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. 2002. Typhoid fever. New England Journal of Medicine 347: 1770–1782. doi: 10.1056/NEJMra020201.
24. Parry CM, Thuy CT, Dongol S, Karkey A, Vinh H, Chinh NT, Duy PT, Thieu Nga TV, Campbell JI, Van Minh Hoang N, Arjyal A, Bhutta ZA, Bhattacharya SK, Agtini MD, Dong B, Canh DG, Naheed A, Wain J, Tinh Hien T, Basnyat B, Ochiai L, Clemens J, Farrar JJ, Dolecek C, Baker S. 2010. Suitable disk antimicrobial susceptibility breakpoints defining salmonella enterica serovar typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrobial Agents and Chemotherapy 54:5201–5208. doi: 10.1128/AAC.00963-10.
25. Parry CM, Vinh H, Chinh NT, Wain J, Campbell JI, Hien TT, Farrar JJ, Baker S. 2011. The influence of reduced susceptibility to fluoroquinolones in salmonella enterica serovar typhi on the clinical response to ofloxacin therapy. PLoS Neglected Tropical Diseases 5:e1163. doi: 10.1371/journal.pntd.0001163.
26. Roumagnac P, Weill F-X, Dolecek C, Baker S, Brisse S, Chinh NT, Le TAH, Acosta CJ, Farrar J, Dougan G, Achtman M. 2006. Evolutionary history of salmonella typhi. Science 314:1301–1304. doi: 10.1126/science.1134933.
27. Team R. 2012. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria: Open access available http//cran r-project org.
28. The World Health Organization. 2003. Background document: the diagnosis, treatment and management of typohoid fever. http://www.who.int/rpc/TFGuideWHO.pdf.
29. Wain J, Diem Nga LT, Kidgell C, James K, Fortune S, Song Diep T, Ali T, O Gaora P, Parry C, Parkhill J, Farrar J, White NJ, Dougan G. 2003. Molecular analysis of incHI1 antimicrobial resistance plasmids from salmonella serovar typhi strains associated with typhoid fever. Antimicrobial Agents and Chemotherapy 47:2732–2739. doi: 10.1128/AAC.47.9.2732-2739.2003.
30. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, Kingsley RA, Thomson NR, Keane JA, Weill F-X, Edwards DJ, Hawkey J, Harris SR, Mather AE, Cain AK, Hadfield J, Hart PJ, Thieu NTV, Klemm EJ, Glinos DA, Breiman RF, Watson CH, Kariuki S, Gordon MA, Heyderman RS, Okoro C, Jacobs J, Lunguya O, Edmunds WJ, Msefula C, Chabalgoity JA, Kama M, Jenkins K, Dutta S, Marks F, Campos J, Thompson C, Obaro S, MacLennan CA, Dolecek C, Keddy KH, Smith AM, Parry CM, Karkey A, Mulholland EK, Campbell JI, Dongol S, Basnyat B, Dufour M, Bandaranayake D, Naseri TT, Singh SP, Hatta M, Newton P, Onsare RS, Isaia L, Dance D, Davong V, Thwaites G, Wijedoru L, Crump JA, De Pinna E, Nair S, Nilles EJ, Thanh DP, Turner P, Soeng S, Valcanis M, Powling J, Dimovski K, Hogg G, Farrar J, Holt KE, Dougan G. 2015. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of salmonella typhi identifies inter- and intracontinental transmission events. Nature Genetics 47:632–639. doi: 10.1038/ng.3281